Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Sentiment AnalystHold
Sentiment Score4/10
Generated At:2026-04-17 17:41:55
Analysis based on 20 news articles sourced from financial analysis firms (Zacks, Barchart), media outlets (24/7 Wall St., Motley Fool), and financial news aggregators (Yahoo Finance via Insider Monkey, Simply Wall St.), including analyst data from UBS and BofA. Data time range: April 11 to April 17, 2026. Data is current and highly relevant ahead of Pfizer's Q1 2026 earnings cycle. No significant lag issues are present.
News Overview

The news impact on Pfizer's price is expected to be moderate in the short-term (±3% to ±6% post-earnings) with a neutral to slightly negative sentiment ahead of Q1 2026 results, while long-term impact depends on pipeline execution. Investment recommendation is Hold, with the stock likely range-bound ($26-$27.50) until earnings provide new data.

Positive
2
Neutral
2
Negative
1
Event Timeline
2026-04-13
Price Impact: ±0% to ±1%
short-term
Pfizer's stock showed positive day-trading action on April 13, closing at $27.34. This occurs against a backdrop of significant weakness in peer Abbott Laboratories and strong growth in Eli Lilly, framing Pfizer's performance as relatively stable but lacking excitement compared to sector leaders.
2026-04-12
Price Impact: ±0% to ±2% (range-bound)
short-term
Analyst revisions in mid-April 2026 reflect uncertainty, with UBS raising its price target to $27 from $25 on April 15, while BofA lowered its target to $26 from $27 on April 12. This establishes a consensus trading range in the mid-$20s and indicates mixed near-term expectations.
2026-04-11
Price Impact: -3% to -6% (post-earnings potential)
short-term
Multiple news sources indicate Pfizer's Q1 2026 earnings report in early May is the key near-term catalyst. Analysts anticipate a profit decline, with attention on the strength of non-COVID drugs like Eliquis and Prevnar versus significant drops in COVID product revenue. This sets a cautious tone ahead of the report.
2026-04-11
Price Impact: +1% to +5% (long-term potential)
long-term
News highlights Pfizer's long-term strategy to rebuild its growth pipeline, including a push to form partnerships with Chinese biotech companies. A comparative analysis with AbbVie underscores the market view that Pfizer's future depends on R&D success, contrasting with AbbVie's stronger commercial moat.
2026-04-11
Price Impact: +1% to +3% (supportive)
medium-term to long-term
A consistent theme across multiple news items is Pfizer's high dividend yield, making it a recommended stock for generating substantial annual income. This positions Pfizer as appealing to value and income investors, providing downside support and a valuation floor despite near-term growth challenges.
News Topics List

Upcoming Q1 2026 Earnings Preview and Analyst Expectations

2026-04-11neutral to slightly negativePrice Impact: -3% to -6% (post-earnings potential)short-term
AI Key Summary
  • The most timely news cluster centers on Pfizer's impending Q1 2026 earnings report expected in early May.
  • Analysts expect a challenging quarter with profits anticipated to decline in the low double-digit range.
  • The focus will be on the non-oncology portfolio, where gains from drugs like Eliquis and Prevnar are projected to be offset by significant declines in COVID products Comirnaty and Paxlovid.
  • This sets a cautious tone ahead of the report.
Source

Diverging Analyst Price Target Revisions and Neutral Ratings

2026-04-12neutralPrice Impact: ±0% to ±2% (range-bound)short-term
AI Key Summary
  • Analyst actions show a divergence in near-term price expectations, though both maintain a 'Neutral' rating.
  • UBS raised its price target on PFE to $27 from $25 on April 15.
  • BofA lowered its price target to $26 from $27 on April 12.
  • This tug-of-war reflects uncertainty in modeling the post-COVID transition but suggests a consensus trading range in the mid-$20s.
Source

Strategic Initiatives: China Partnerships and Pipeline Rebuild

2026-04-11neutral to positivePrice Impact: +1% to +5% (long-term potential)long-term
AI Key Summary
  • News highlights Pfizer's strategic moves to rebuild its long-term growth pipeline.
  • This includes a push to form drug development partnerships with Chinese biotech companies, broadening its R&D footprint.
  • A comparative analysis with AbbVie underscores the market's view that Pfizer is in a 'pipeline hit' prayer phase.
  • This contrasts with AbbVie's perceived stronger commercial moat, placing pressure on Pfizer's R&D execution.
Source

Strong Dividend Narrative and Income Investor Appeal

2026-04-11positivePrice Impact: +1% to +3% (supportive)medium-term to long-term
AI Key Summary
  • A consistent theme across multiple news items is Pfizer's high dividend yield.
  • It is frequently listed among stocks that can generate substantial annual income from a fixed investment.
  • This positions Pfizer as a core holding for income-focused portfolios.
  • It highlights its appeal to value and income investors despite its growth challenges.
  • The dividend provides income support and a valuation floor.
Source

Recent Market Performance and Peer Sector Context

2026-04-13neutralPrice Impact: ±0% to ±1%short-term
AI Key Summary
  • Pfizer's stock outperformed the broader market on April 13, closing at $27.34.
  • This positive day-trading action occurs against a backdrop of significant weakness in a peer (Abbott Laboratories, down 26% over five months).
  • It also contrasts with towering strength in another peer (Eli Lilly, cited for its growth trajectory).
  • This frames Pfizer's performance as relatively stable but unexciting within the sector.
Source